Hetero launches first-ever ‘Patient Compliant Pack’ of Favivir for Covid-19 treatment in India

Hyderabad, Sep 25 (UNI) Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of antiretroviral drugs, on Friday claimed that it has launched the first-ever ‘Patient Compliant Pack’ of Favivir 800/200 mg for the treatment of mild-to-moderate symptomatic Covid-19 patients in the country.

Favivir will be available in a patient-friendly pack containing 16 tablets of 800 mg and 2 tablets of 200 mg, which is priced both at Rs 2,640, Hyderabad-based pharmaceutical company said in a release here.

The higher strength of Favivir 800 mg from Hetero has been approved by the Drug Controller General of India (DCGI).

The product will be marketed and distributed by Hetero Healthcare Limited.

The launch of ‘Favivir 800/200’ mg is aimed at enhancing patients’ adherence to treatment regimen by reducing the number of pills they are required to consume per day.

The initial regimen of Favipiravir 200mg requires patients to consume a total of 122 tablets for the 14-day treatment course. However, with the new Favivir 800/200 mg pack, the pill intake number is reduced to 32 tablets, effectively cutting down the pill burden by nearly 75 per cent, leading to better treatment outcomes, it said.

Favivir is the second drug developed by Hetero after Covifor (Remdesivir) used in the treatment of Covid-19. It is an oral antiviral medication that has shown positive clinical outcomes.

The product will be made available at all retail medical outlets and hospital pharmacies across the country and sold only on prescription.

Backed by strong vertical integration capabilities, the drug is being manufactured at our world-class formulation facility in India, approved by stringent global regulatory authorities.

Favivir has been the most prescribed brand in the market, as per IPM July’20.


Please enter your comment!
Please enter your name here